Topera Medical, a developer of innovative mapping systems that help identify the electrical source of cardiac arrhythmias announced that the RhythmView diagnostic system will be utilised as part of a complex procedure demonstration on 12 January at the 17th Annual Boston Atrial Fibrillation Symposium.
Sanjiv Narayan, professor of Medicine at the University of California, San Diego, and the San Diego VA Medical Center will perform the procedure, which will involve using the diagnostic RhythmView technology during a procedure to treat a patient with persistent atrial fibrillation. Researchers previously demonstrated for the first time the ability of RhythmView to graphically display unique, patient-specific sources that perpetuate arrhythmias in the landmark CONFIRM trial presented last May at the Heart Rhythm Society Annual Meeting.
“Focal impulse and rotor mapping (FIRM) with the Topera technology enables us to accurately target the small, localised areas of the heart that cause these arrhythmias and perform successful procedures in these complex patients,” said Narayan. “Further, in our lab we have found that FIRM-guided procedures are much easier to perform than other current approaches. Our hope is that this will provide the opportunity for many more physicians to treat their patients quickly and successfully.”
The RhythmView system was cleared by the FDA last September, and Topera is in the process of initiating clinical user-preference testing with a number of leading electrophysiologists throughout the USA. “We are encouraged by the early results of the user-preference testing and are pleased that there is considerable interest and support for Topera’s diagnostic technology from the broader clinical and scientific community, as evidenced by this demonstration at the Boston Atrial Fibrillation Symposium,” said Ruchir Sehra, co-founder and chief medical officer of Topera Medical. “Successful testing combined with the health economic data from the CONFIRM trial, which demonstrated substantial cost savings over two years when FIRM guidance was utilised, will hopefully set the path to FIRM becoming a standard diagnostic tool used in these electrophysiology procedures.”
